Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$83.08

0.64 (0.78%)

06:51
05/15/18
05/15
06:51
05/15/18
06:51

Eli Lilly chronic cluster headache Phase 3 study did not meet primary endpoint

Eli Lilly also conducted a separate Phase 3 study for patients with chronic cluster headache, which represents 10 to 15 percent of cluster headache cases.1 This study did not meet its primary endpoint. Based on results from the episodic cluster headache trial, Lilly is working with regulatory agencies around the world to determine the best path forward. Episodic cluster headache represents 85 to 90 percent of cluster headache cases. These studies, which evaluated a combined 343 patients, are the largest controlled preventive trials conducted in cluster headache to date. "It is hard to articulate the devastating impact that cluster headache can have on those of us living with the disease. Many people living with cluster headache spend years searching for effective treatment options to help ease an excruciating level of pain," said Bob Wold, a patient living with cluster headache and founder of Clusterbusters, Inc. "We are very excited by these results and galcanezumab's potential as a new treatment option for people living with cluster headache, many of whom have spent years feeling ignored and alone in their struggle." The episodic cluster headache study included a two-month treatment period comparing galcanezumab to placebo. Patients with episodic cluster headache treated with galcanezumab experienced statistically significant differences in the reduction of weekly cluster headache attacks compared to patients treated with placebo across weeks one to three of the two-month, double-blind treatment period, the primary endpoint of the study. In May 2017, Lilly announced positive data from three Phase 3 studies evaluating galcanezumab for the treatment of chronic and episodic migraine. In these studies, galcanezumab demonstrated statistically significant reductions in the number of monthly migraine headache days compared to placebo at both studied doses. The FDA is currently reviewing galcanezumab for the prevention of migraine in adults. A decision is expected in the third quarter of 2018.

  • 15

    May

  • 15

    May

  • 21

    May

  • 07

    Jun

LLY Eli Lilly
$83.08

0.64 (0.78%)

04/13/18
BMOC
04/13/18
UPGRADE
Target $79
BMOC
Market Perform
Eli Lilly upgraded to Market Perform at BMO Capital on valuation
As reported earlier, BMO Capital analyst Alex Arfaei upgraded Eli Lilly to Market Perform from Underperform and raised his price target to $79 from $74. The analyst believes that his previously expressed concerns around the downside risks for Humalog, cautious outlook for Vernezio, and uncertainty around Bari are "mostly reflected" in the stock, with more balance in risk-reward going forward. While he anticipates 2018 to be volatile as maturing diabetes franchise constrains the company's growth plans, Arfaei also sees some tailwinds for Eli Lilly around continued strong growth of Trulicity, further growth of Taltz, Jardiance, and Basglar, as well as potential divestiture of Elanco.
04/13/18
04/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: Netflix (NFLX) upgraded to Buy from Hold at Deutsche Bank with analyst Bryan Kraft saying he underestimated the market's willingness to underwrite several years of negative free cash flow to drive growth. 2. Eli Lilly (LLY) upgraded to Market Perform from Underperform at BMO Capital with analyst Alex Arfaei saying he believes that his previously expressed concerns around the downside risks for Humalog, cautious outlook for Vernezio, and uncertainty around Bari are "mostly reflected" in the stock, with more balance in risk-reward going forward. 3. Willis Towers Watson (WLTW) upgraded to Buy from Hold at Sandler O'Neill with analyst Paul Newsome saying he is making a valuation call with the stock down to "both absolute and relative valuations that we have not seen since there were significant concerns about the Willis/Towers Watson merger and the company's ability to generate organic growth." 4. Shaw Communications (SJR) upgraded to Buy from Hold at Canaccord and to Outperform from Sector Perform at Scotiabank. 5. eBay (EBAY) upgraded to Buy from Neutral at Monness Crespi with analyst Jim Chartier saying eBay's structured data initiatives have meaningfully improved the eBay marketplace experience for buyers and sellers, resulting in gross merchandise value inflecting to up 7% in the fourth quarter of 2017 from up 1% in the third quarter of 2016. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/23/18
RBCM
04/23/18
NO CHANGE
RBCM
Outperform
Incyte AdCom meeting going more favorably than docs suggested, says RBC Capital
RBC Capital analyst Brian Abrahams said the FDA advisory committee meeting for baricitinib, a rheumatoid arthritis treatment developed by Incyte (INCY) and submitted for review by Eli Lilly (LLY), seems "considerably less negative" than the briefing documents for the meeting had suggested. He sees the tone of the panel and the panelist Q&A suggesting a high likelihood that baricitinib will be approved, with the potential still existing that even a 4mg version could be approved in some form. Abrahams has an Outperform rating and $75 price target on Incyte shares.
04/25/18
DBAB
04/25/18
NO CHANGE
DBAB
Hold
Merck may need to reassess animal health unit, says Deutsche Bank
While Merck (MRK) describes its animal health unit as a key growth driver and an important part of the company, it remains to be seen whether investors will continue to accept this as a reason for the business to remain within the company, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. He believes the unit is potentially undervalued. Given Zoetis' (ZTS) success as a company and a stock, and Eli Lilly's (LLY) ongoing review of strategic options for its Elanco Animal Health business, Gilbert conducted a preliminary separation analysis of Merck's animal health unit. The analysis suggests that a separation could be meaningfully accretive to earnings. The analyst keeps a Hold rating on Merck.

TODAY'S FREE FLY STORIES

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/20/18
05/20
04:55
05/20/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

CBS

CBS

$51.75

0.14 (0.27%)

, VIA

Viacom

$33.80

-0.75 (-2.17%)

13:23
05/19/18
05/19
13:23
05/19/18
13:23
Periodicals
CBS looks like a bargain, Barron's says »

In a follow-up story,…

CBS

CBS

$51.75

0.14 (0.27%)

VIA

Viacom

$33.80

-0.75 (-2.17%)

VIAB

Viacom

$27.24

-0.92 (-3.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

, PEP

PepsiCo

$97.51

-0.45 (-0.46%)

13:10
05/19/18
05/19
13:10
05/19/18
13:10
Periodicals
Coca-Cola, PepsiCo look like bargains, Barron's says »

Investors have punished…

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

PEP

PepsiCo

$97.51

-0.45 (-0.46%)

KO

Coca-Cola

$42.18

-0.13 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$35.40

1.14 (3.33%)

10:32
05/19/18
05/19
10:32
05/19/18
10:32
Periodicals
Roku relevance worth taking note of, Barron's says »

Roku now is mostly a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

LOW

Lowe's

$86.31

0.85 (0.99%)

10:19
05/19/18
05/19
10:19
05/19/18
10:19
Periodicals
Lowe's turnaround what matters for long-term investors, Barron's says »

With Lowe's shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AAPL

Apple

$186.31

-0.69 (-0.37%)

, ZTCOY

ZTE Corp.

$0.00

(0.00%)

08:41
05/19/18
05/19
08:41
05/19/18
08:41
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$186.31

-0.69 (-0.37%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

ACIA

Acacia Communications

$32.97

0.45 (1.38%)

OCLR

Oclaro

$8.88

-0.015 (-0.17%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba, also use TOSBF

$0.00

(0.00%)

GM

General Motors

$37.80

-0.51 (-1.33%)

F

Ford

$11.33

-0.12 (-1.05%)

FCAU

Fiat Chrysler

$21.86

-0.31 (-1.40%)

HMC

Honda

$32.98

-0.11 (-0.33%)

TM

Toyota

$136.04

-0.54 (-0.40%)

NSANY

Nissan

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

VRX

Valeant

$22.15

0.12 (0.54%)

PFE

Pfizer

$35.64

-0.07 (-0.20%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

INSY

Insys Therapeutics

$6.95

-0.37 (-5.05%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

BAYRY

Bayer

$0.00

(0.00%)

GILD

Gilead

$68.01

0.41 (0.61%)

BMRN

BioMarin

$88.95

0.51 (0.58%)

MNK

Mallinckrodt

$15.70

-0.37 (-2.30%)

SHPG

Shire

$169.62

-2.18 (-1.27%)

MRK

Merck

$59.13

0.06 (0.10%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

TEVA

Teva

$21.23

0.12 (0.57%)

AZN

AstraZeneca

$36.34

-0.09 (-0.25%)

ACOR

Acorda Therapeutics

$23.65

-0.45 (-1.87%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

NVS

Novartis

$77.08

-0.07 (-0.09%)

RHHBY

Roche

$0.00

(0.00%)

GALE

Galena

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 24

    May

  • 25

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 22

    Aug

  • 27

    Aug

  • 07

    Sep

  • 10

    Sep

  • 12

    Sep

  • 05

    Oct

  • 23

    Oct

  • 13

    Nov

  • 20

    Dec

  • 21

    Dec

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/19/18
05/19
04:55
05/19/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

SLDB

Solid Biosciences

$21.96

-0.79 (-3.47%)

18:46
05/18/18
05/18
18:46
05/18/18
18:46
Hot Stocks
Solid Biosciences announces new preclinical data for SGT-001 »

Solid Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

18:04
05/18/18
05/18
18:04
05/18/18
18:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 2.4K…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

GLD

SPDR Gold Trust

$122.42

0.06 (0.05%)

FXE

Euro Currency Trust

$113.01

-0.28 (-0.25%)

FXC

CurrencyShares Canadian Dollar Trust

$76.61

-0.38 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$114.04

0.11 (0.10%)

18:02
05/18/18
05/18
18:02
05/18/18
18:02
Hot Stocks
Celanese raises prices for emulsion polymers and acetyls »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

JBHT

J.B. Hunt

$126.85

1.06 (0.84%)

18:01
05/18/18
05/18
18:01
05/18/18
18:01
Hot Stocks
J.B. Hunt director Garrison sells 100,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$36.34

-0.09 (-0.25%)

17:56
05/18/18
05/18
17:56
05/18/18
17:56
Hot Stocks
AstraZeneca confirms FDA approval of Lokelma »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

XLE

Energy Select Sector SPDR

$78.11

-0.62 (-0.79%)

, XLU

Utilities SPDR

$48.97

-0.02 (-0.04%)

17:48
05/18/18
05/18
17:48
05/18/18
17:48
General news
Week ending ETF Scorecard: Energy rallies while Utilities and Real Estate slide »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$78.11

-0.62 (-0.79%)

XLU

Utilities SPDR

$48.97

-0.02 (-0.04%)

IYR

DJ US Real Estate Index Fund

$75.47

0.15 (0.20%)

XLP

Consumer Staples Sector SPDR

$49.53

-0.33 (-0.66%)

XLY

Consumer Discretionary Sector SPDR

$104.87

-0.12 (-0.11%)

XLB

S&P Select Materials SPDR

$59.87

0.09 (0.15%)

XLF

Financial Select Sector

$27.95

-0.255 (-0.90%)

XLV

Health Care Select Sector SPDR

$83.23

0.24 (0.29%)

XLK

Technology Select Sector SPDR

$68.89

-0.28 (-0.40%)

XLI

Industrial Select Sector SPDR

$75.34

0.45 (0.60%)

GLD

SPDR Gold Trust

$122.42

0.06 (0.05%)

SLV

iShares Silver Trust

$15.48

-0.005 (-0.03%)

USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

UNG

United States Natural Gas Fund

$23.19

-0.085 (-0.37%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.38

-0.095 (-0.11%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$114.28

0.475 (0.42%)

TLT

iShares 20+ Year Treasury Bond Fund

$117.21

0.98 (0.84%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.76

0.4 (0.40%)

SHY

iShares 1-3 Year Treasury Bond

$83.18

0.05 (0.06%)

IWD

iShares Russell 1000 Value

$122.33

-0.49 (-0.40%)

IWF

iShares Russell 1000 Growth

$141.58

-0.03 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHN

athenahealth

$150.09

0.64 (0.43%)

17:37
05/18/18
05/18
17:37
05/18/18
17:37
Hot Stocks
Janus Henderson reports 11.9% stake in athenahealth, urges for sale process »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 06

    Jun

YGYI

Youngevity International

$3.90

-0.08 (-2.01%)

17:33
05/18/18
05/18
17:33
05/18/18
17:33
Syndicate
Breaking Syndicate news story on Youngevity International »

Youngevity International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTCOY

ZTE Corp.

$0.00

(0.00%)

17:32
05/18/18
05/18
17:32
05/18/18
17:32
Periodicals
Kudlow: ZTE needs to overhaul management to get U.S. reprieve, Bloomberg says »

White House National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PF

Pinnacle Foods

$63.23

-0.45 (-0.71%)

, CAG

Conagra Brands

$37.43

-0.28 (-0.74%)

17:31
05/18/18
05/18
17:31
05/18/18
17:31
Periodicals
Pinnacle Foods hires Evercore Partners to examine alternatives, NY Post says »

Pinnacle Foods (PF) has…

PF

Pinnacle Foods

$63.23

-0.45 (-0.71%)

CAG

Conagra Brands

$37.43

-0.28 (-0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

MYND

MYnd Analytics

$3.28

0.075 (2.34%)

17:25
05/18/18
05/18
17:25
05/18/18
17:25
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INWK

InnerWorkings

$8.71

-0.08 (-0.91%)

17:16
05/18/18
05/18
17:16
05/18/18
17:16
Hot Stocks
InnerWorkings receives Nasdaq non-compliance letter due to late 10-Q filing »

InnerWorkings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

ADMA

ADMA Biologics

$5.46

0.05 (0.92%)

17:05
05/18/18
05/18
17:05
05/18/18
17:05
Syndicate
Breaking Syndicate news story on ADMA Biologics »

ADMA Biologics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADMA

ADMA Biologics

$5.46

0.05 (0.92%)

17:05
05/18/18
05/18
17:05
05/18/18
17:05
Syndicate
Breaking Syndicate news story on ADMA Biologics »

ADMA Biologics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLDB

Solid Biosciences

$21.96

-0.79 (-3.47%)

17:04
05/18/18
05/18
17:04
05/18/18
17:04
Hot Stocks
Breaking Hot Stocks news story on Solid Biosciences »

Boxer Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDIT

Editas Medicine

$34.85

-3.14 (-8.27%)

17:03
05/18/18
05/18
17:03
05/18/18
17:03
Hot Stocks
Editas Medicine data shows subretinal EDIT-101 injection tolerated in primates »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMBA

Jamba

$9.57

-0.09 (-0.93%)

17:03
05/18/18
05/18
17:03
05/18/18
17:03
Hot Stocks
Jamba announces expected receipt of Nasdaq letter »

Jamba, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLIC

Kulicke & Soffa

$21.98

-0.84 (-3.68%)

17:03
05/18/18
05/18
17:03
05/18/18
17:03
Hot Stocks
Kulicke & Soffa receives Nasdaq notice of non-compliance »

Kulicke and Soffa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.